Related references
Note: Only part of the references are listed.Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Atsushi Yonezawa et al.
CLINICAL CANCER RESEARCH (2015)
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Daniel Sanghoon Shin et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Thymus-derived regulatory T cells restrain pro-inflammatory Th1 responses by downregulating CD70 on dendritic cells
Maxime Dhainaut et al.
EMBO JOURNAL (2015)
Immuno-regulatory antibodies for the treatment of cancer
Jamie Honeychurch et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
The association of CTLA-4 A49G polymorphism with colorectal cancer risk in a Chinese Han population
Y. Wang et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2015)
Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese
Jie Ge et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Harnessing the Therapeutic Potential of Th17 Cells
Jonas Bystrom et al.
MEDIATORS OF INFLAMMATION (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CD70: An emerging target in cancer immunotherapy
J. Jacobs et al.
PHARMACOLOGY & THERAPEUTICS (2015)
The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
Yanping Xiao et al.
CANCER DISCOVERY (2015)
Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
Julie Jacobs et al.
ONCOTARGET (2015)
Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer
Benling Xu et al.
ONCOTARGET (2015)
Colorectal Cancer Biomarkers: Where Are We Now?
Maria Gonzalez-Pons et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models
Soledad Mac Keon et al.
FRONTIERS IN IMMUNOLOGY (2015)
An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy
Neeraj Lal et al.
ONCOIMMUNOLOGY (2015)
4-1 BB agonists: multi-potent potentiators of tumor immunity
Todd Bartkowiak et al.
FRONTIERS IN ONCOLOGY (2015)
OX40 agonists anc combination immunotherapy: putting the pedal to the metal
Stefanie N. Linch et al.
FRONTIERS IN ONCOLOGY (2015)
The potential role of immunotherapy to treat colorectal cancer
Manik Amin et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Optimal delivery of colorectal cancer follow-up care: improving patient outcomes
Mikaela L. Jorgensen et al.
PATIENT-RELATED OUTCOME MEASURES (2015)
Impact of the immune system and immunotherapy in colorectal cancer
Janet L. Markman et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2015)
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
Dass S. Vinay et al.
BMB REPORTS (2014)
PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients
X. Wu et al.
BRITISH JOURNAL OF CANCER (2014)
被撤回的出版物: Targeting CD137 enhances the efficacy of cetuximab (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
Kristina M. Ilieva et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells
M. Scurr et al.
MUCOSAL IMMUNOLOGY (2014)
The effect of immune microenvironment on the progression and prognosis of colorectal cancer
Jinxiang Chen et al.
MEDICAL ONCOLOGY (2014)
Colorectal cancer and immunity: what we know and perspectives
Simon Pernot et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Th17 cellsin cancer: the ultimate identity crisis
Stefanie R. Bailey et al.
FRONTIERS IN IMMUNOLOGY (2014)
CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies
Roch Houot et al.
ONCOIMMUNOLOGY (2014)
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
Lawrence J. Thomas et al.
ONCOIMMUNOLOGY (2014)
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
Zachary A. Cooper et al.
ONCOIMMUNOLOGY (2014)
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
David A. Schaer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
FGFR4 Promotes Stroma-Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer
Rui Liu et al.
CANCER RESEARCH (2013)
CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma
Koji Ohnishi et al.
CANCER SCIENCE (2013)
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
Raoul A. Droeser et al.
EUROPEAN JOURNAL OF CANCER (2013)
Infiltration of CD40-Positive Tumor-Associated Macrophages Indicates a Favorable Prognosis in Colorectal Cancer Patients
Makoto Kinouchi et al.
HEPATO-GASTROENTEROLOGY (2013)
Activated tumor-infiltrating CD4+regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer
Alexander Pedroza-Gonzalez et al.
HEPATOLOGY (2013)
Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer
Yung-Chang Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Nicola Gagliani et al.
NATURE MEDICINE (2013)
Tumor stroma as targets for cancer therapy
Jing Zhang et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer
Julie R. Brahmer et al.
CANCER IMMUNOLOGY RESEARCH (2013)
GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
David A. Schaer et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Macrophages Good guys in colorectal cancer
Sofia Edin et al.
ONCOIMMUNOLOGY (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
Toward a molecular classification of colorectal cancer: the role of microsatellite instability status
Karl Heinimann
FRONTIERS IN ONCOLOGY (2013)
Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer
Vanessa Deschoolmeester et al.
CURRENT COLORECTAL CANCER REPORTS (2013)
CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
Christina Claus et al.
CANCER RESEARCH (2012)
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
Esdy N. Rozali et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer
Zahra Mojtahedi et al.
GENE (2012)
Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer
Gareth Betts et al.
GUT (2012)
Cancer-associated fibroblasts as targets for immunotherapy
Sunitha Kakarla et al.
IMMUNOTHERAPY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Accumulation of CCR4+ CTLA-4hi FOXP3+CD25hi Regulatory T Cells in Colon Adenocarcinomas Correlate to Reduced Activation of Conventional T Cells
Helena Svensson et al.
PLOS ONE (2012)
B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma
Dong Hua et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence
Petr Kocian et al.
HUMAN IMMUNOLOGY (2011)
Role of CD27/CD70 pathway of activation in immunity and tolerance
Julie Denoeud et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer
Marco Erreni et al.
CANCER MICROENVIRONMENT (2011)
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
Vanessa Deschoolmeester et al.
BMC IMMUNOLOGY (2010)
Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75
M. C. Ryan et al.
BRITISH JOURNAL OF CANCER (2010)
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
Jun Mitsui et al.
CLINICAL CANCER RESEARCH (2010)
A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival
Richard J. Barth et al.
CLINICAL CANCER RESEARCH (2010)
Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Ki Y. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
Chiara Camisaschi et al.
JOURNAL OF IMMUNOLOGY (2010)
A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy
Vanessa Deschoolmeester et al.
ONCOLOGIST (2010)
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Raul Elgueta et al.
IMMUNOLOGICAL REVIEWS (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma
Heena Patel et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival
Dirk Nagorsen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Immunotherapy and immunoescape in colorectal cancer
Guillermo Mazzolini et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
CD40-mediated death and cytokine secretion in colorectal cancer: A potential target for inflammatory tumour cell killing
Nikolaos T. Georgopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associllited T cells
Michael R. Nazareth et al.
JOURNAL OF IMMUNOLOGY (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth
AJ Baxendale et al.
ONCOGENE (2005)
Effects of loss of p53 and p16 function on life span and survival of human urothelial cells
NJ Shaw et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Serum concentrations of soluble 4-1BB and 4-BB ligand correlated with the disease severity in rheumatoid arthritis
HW Jung et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2004)
Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A
M Liljefors et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)
JK Petty et al.
AMERICAN JOURNAL OF SURGERY (2002)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation
SH Chen et al.
MOLECULAR THERAPY (2000)
Share Paper
